IgA nephropathy is the most common form of glomerulonephritis in the world, and it has a habit of staying quiet. Many people carry it for years — sometimes decades — before a routine blood pressure check or a urine test picks up the first clue. Understanding how this disease behaves, and why catching it early matters so much, can change the course of a person's kidney health.
What Is IgA Nephropathy?
IgA nephropathy, also called Berger's disease, is a kidney condition in which an antibody called immunoglobulin A (IgA) forms abnormal clusters and deposits itself in the glomeruli — the tiny filtering units inside the kidneys. Over time, these deposits trigger inflammation that can scar the filtering units and gradually reduce the kidney's ability to clean the blood.
It is one of the most common causes of primary glomerular disease worldwide and can affect people of any age, though it is diagnosed most often between the teenage years and the thirties. It occurs somewhat more often in men, and rates are notably higher in parts of Asia, suggesting a genetic and ethnic pattern to who develops it.
Why It's Often Called the "Silent" Kidney Disease
For most people, IgA nephropathy does not announce itself with dramatic symptoms. The kidneys have a large filtering reserve, so they can quietly compensate for a significant loss of function before a person feels unwell. This is exactly what makes the disease risky: patients often feel completely normal while inflammation is slowly scarring kidney tissue in the background.
Some people do notice a brief episode of cola-coloured or bloody urine, usually a day or two after a cold, sore throat, or stomach bug — a pattern doctors call synpharyngitic hematuria. But this episode often clears up on its own, and without a specific reason to test the urine again, it's easy to dismiss and forget.
How It Usually Shows Up: High Blood Pressure and Kidney Impairment
Because IgA nephropathy rarely causes obvious early symptoms, it is frequently discovered incidentally — during a routine health check, an insurance medical exam, a pregnancy screening, or a visit for something entirely unrelated.
- New or difficult-to-control high blood pressure, especially in a younger adult with no other obvious cause
- Signs of kidney impairment on blood and urine tests — persistent protein in the urine (proteinuria), microscopic blood invisible to the naked eye (hematuria), or a gradually falling eGFR, which measures how well the kidneys are filtering blood
Because both hypertension and mild kidney impairment can exist quietly for years, either one turning up on a routine test is reason enough to look further — not just treat the number in isolation.
- A blood pressure reading that is high, new, or hard to control, particularly if you're under 40
- Urine that looks pink, cola-coloured, or bloody, especially after a cold or throat infection
- Persistent puffiness around the eyes, ankles, or feet
- Unexplained fatigue that doesn't improve with rest
- A family history of kidney disease or kidney failure
- Protein or blood flagged on a routine urine test, even if you feel completely fine.
How Doctors Diagnose IgA Nephropathy
Diagnosis usually starts with simple, non-invasive tests and moves toward more definitive ones only as needed.
- Urinalysis to check for blood and protein in the urine — often the first clue.
- Blood tests, including serum creatinine and eGFR, to see how well the kidneys are filtering, alongside a blood pressure check and sometimes serum IgA levels
- Imaging, usually a kidney ultrasound, to rule out structural causes like stones, cysts, or obstruction
- Kidney biopsy, which remains the only way to confirm the diagnosis with certainty
A biopsy is not needed for everyone with mild findings, but it becomes important when protein loss is significant, kidney function is declining, or blood pressure is difficult to control. Under the microscope, a small sample of kidney tissue reveals the IgA deposits that give the disease its name, and the pattern of scarring seen on biopsy helps predict how the disease is likely to behave and guides treatment choices.
Why Early Identification Changes the Outcome
IgA nephropathy behaves differently from person to person. Some people have a mild course that never threatens kidney function, while others slowly progress toward chronic kidney disease and, in a meaningful proportion of cases, kidney failure requiring dialysis or transplantation over 10 to 20 years. What separates a mild course from a serious one is often not the disease itself, but how early it is caught and how consistently it is managed.
Once significant scarring, or fibrosis, has occurred in the kidney, it cannot be reversed. Every additional year of uncontrolled blood pressure or unchecked protein loss adds to that scarring. Catching the disease while kidney function is still largely preserved gives doctors far more room to slow — and sometimes essentially halt — its progression.
The kidneys rarely complain until most of the damage is already done. A high blood pressure reading or a trace of protein in a routine urine test isn't something small to brush aside — it's often the only warning IgA nephropathy gives.
Current and Newer Medicines That Help Prevent Kidney Failure
Treatment for IgA nephropathy has expanded significantly in recent years, moving beyond simply controlling blood pressure to a layered approach that specifically targets the disease process.
- ACE inhibitors and ARBs (angiotensin-converting enzyme inhibitors and angiotensin receptor blockers) remain the foundation of treatment. They lower blood pressure and independently reduce protein leaking into the urine, easing strain on the filtering units. Current guidelines recommend pushing these to the maximum tolerated dose before adding other agents
- SGLT2 inhibitors, originally developed for diabetes, have been shown in large trials to slow kidney function decline and reduce proteinuria in IgA nephropathy, and are now commonly added alongside ACE inhibitors or ARBs for patients with persistent protein loss
- Newer targeted therapies are now available for people whose disease keeps progressing despite the above. These include a targeted-release form of the steroid budesonide, designed to act specifically where the IgA deposits originate, and sparsentan, an oral medicine that blocks both endothelin and angiotensin receptors together. Both have received regulatory approval specifically for IgA nephropathy in recent years, based on trial evidence of reduced protein loss and slower decline in kidney function
- For a smaller group with more aggressive inflammation, doctors may also consider immunosuppressive medicines, used selectively after carefully weighing their risks and benefits
None of these medicines are interchangeable, one-size-fits-all choices, and availability of the newer therapies can vary by country. The right combination depends on how much protein is being lost, current kidney function, blood pressure control, and the biopsy findings. This is a conversation to have with a nephrologist, ideally started as early as possible.
Sources
Frequently asked questions
Most people have no early signs at all. When something does show up, it's usually either a brief episode of cola-coloured or bloody urine within a day or two of a cold or throat infection, or an abnormal finding on a routine test — high blood pressure, protein in the urine, or microscopic blood that isn't visible without a lab test.
Written by Dr. Chinta Rama Krishna
All ArticlesHave a health concern? Talk to a specialist.
Book a consultation with the Vedanta Hospitals team for advice tailored to you.
Book Appointment